Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Oropharyngeal CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
RADIATION

Standard Radiation Treatment

An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.

RADIATION

Dose-Deescalated Treatment

Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons

DRUG

Cisplatinum

Standard of care chemotherapy

Trial Locations (1)

10016

RECRUITING

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER